BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Beam Therapeutics Inc.

Headquarters: Cambridge, MA, United States of America
Year Founded: 2017
Status: Public
Industry Sector: HealthTechnology
CEO: John Evans, MBA
Number Of Employees: 436
Enterprise Value: $1,083,370,000
PE Ratio: -15.11
Exchange/Ticker 1: NASDAQ:BEAM
Exchange/Ticker 2: N/A
Latest Market Cap: $2,376,520,704

BioCentury | Dec 10, 2024
Product Development

Gene and base editors deliver on fetal hemoglobin expression: ASH24

Editas, Beam report updates on sickle cell genetic therapies at this year’s ASH meeting
BioCentury | Dec 5, 2024
Discovery & Translation

Science Spotlight: Advances in RSV and hMVP vaccines 

BioCentury’s roundup of translational innovation also features a kinase degrader for breast cancer, and half a dozen papers on product candidates
BioCentury | Nov 5, 2024
Product Development

Arcus data the latest twist in the TIGIT story

BioCentury’s Clinical Report also analyzes the impact of a patient death in Beam’s trial, plus data from Cogent, Disc, Essa and Novo
BioCentury | Oct 22, 2024
Finance

Venture funds, a new chapter for MS & Wave’s data: a BioCentury podcast

What Forbion’s $2.2B raise says about the state of venture, NIH’s Daniel Reich on MS and RNA-editing oligo data from Wave 
BioCentury | Oct 17, 2024
Product Development

Wave data propel RNA-editing stocks, but are all platforms created equal?

In first human RNA-editing data, Wave reports positive results from WVE-006 in alpha-1 antitrypsin deficiency
BioCentury | Aug 30, 2024
Emerging Company Profile

Nvelop: Delivering gene editors to specific cells via virus-like particles

Propelled by $100M in seed funding, Cambridge, Mass.-based biotech is developing dual virus-like particle platforms from two gene editing pioneers 
BioCentury | Jan 26, 2024
Management Tracks

Karuna vet Paul among new Third Rock venture partners

Plus: three new executives at Soleno and updates from Zentalis, Slingshot, Actio, Kronos, Osivax, Cellular Origins and ConcertAI
BioCentury | Jan 13, 2024
Finance

Jan. 12 Quick Takes: Alto Neuroscience files for IPO

Plus: Company-creating research institute Arena BioWorks launches in Kendall Square, and an update from Ji Xing
BioCentury | Dec 21, 2023
Product Development

Diamonds in a rough 2023, predictions for 2024

BioCentury’s analysts look back at a year when innovation was hot but markets were not, and predict what’ll make news in 2024
BioCentury | Dec 19, 2023
Discovery & Translation

Next-gen gene editing at ASH

Non-Cas9 enzymes and strategies to improve ex vivo and in vivo engineering of hematopoietic cells are among the innovations
Items per page:
1 - 10 of 103